Exp063 is a hybrid compound that possesses both the angiotensin II antagonist activity and the β-blocking activity. EXP063 also acts as a partial β-agonist.
AD-35 is a neuroprotectant for treating Alzheimer’s diseases by significantly inhibiting the production and release of proinflammatory cytokines TNF-α and IL-1β.